

Lab-on-Chip in Orbit: Bio-Convergent Innovation for Pharma

Company name SpacePharma Website <https://www.spacepharma.health>

CEO name Yossi Yamin

CATEGORY: Biotech/Pharma

SESSIONS

- AI Meets Pharma: Building a Sustainable Value for Biotech AI innovation in Drug Development
- Frontiers in Biochip and Bio-Devices; Advancing Technological Systems with Cutting-Edge Biology

- Executive Summary / Investment Rational Briefly

SpacePharma pioneers automated lab-on-chip (LoC) systems for microgravity research, unlocking new drug discovery and material innovation pathways. At the forefront of bio-convergence, the company fuses biology, engineering, and space technologies.

SpacePharma R&D Israel Ltd recently granted the lucrative EIC-ACCELERATOR BLENDED phase from Horizon-Europe. The scale up grant starts with 2.5m USD plus €7.5m Euro as match equity from the EIB.

- Core Technology

State of the art, Miniaturized, remotely controlled LoC platforms enable complex biological and chemical experiments in space. Unmanned in orbit although it allows remote intervention. The technology eliminates fluidic system limitations, ensuring precise, repeatable space-based assays.

- Product Profile/Pipeline

SpacePharma's microgravity platforms support crystallization, drug testing, and molecular biology applications. Ongoing missions target protein crystallization for improved drug development. Collaborations with pharma and academic institutions are advancing pipeline commercialization. 3D bioprinting as well as skin care longevity and tissue culture are all feasible. This is a complete set of tool to promote Bioconverges and business.

- Business Strategy

Leverage LoC technology to offer contract research services for pharma, generate recurring revenue via payload-as-a-service, and scale with strategic space partnerships. Long-term growth includes proprietary therapeutic R&D.

- What's Next?

Future plans include expanded R&D on microgravity-enabled drug discovery, scale-up of LoC production, strategic/design partnerships, and additional missions. Fundraising is underway to support growth and commercialization.